

May 31, 2012



## Rigel Announces Participation at Two Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 31, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul Rodriguez, president and chief operating officer of Rigel, will participate at two upcoming investor conferences. **Details of the events are as follows:**

(Logo: <https://photos.prnewswire.com/prnh/20030226/RIGLLOGO>)

Jefferies 2012 Global Healthcare Conference

Presentation Date: June 5, 2012

Time: 2:30 PM ET

Location: New York, NY

Presenter: James M. Gower

Wells Fargo Securities Research & Economics

2012 Healthcare Conference

Presentation Date: June 19, 2012

Time: 1:30 PM ET

Location: Boston, MA

Presenter: Raul Rodriguez

Both events will be webcast live and can be accessed at [www.rigel.com](http://www.rigel.com). Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

### About Rigel ([www.rigel.com](http://www.rigel.com))

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with our partner AstraZeneca; R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma; R333, a topical JAK/SYK inhibitor for discoid lupus; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

Contact: Ryan Maynard  
Phone: 650.624.1284  
Email: [invrel@rigel.com](mailto:invrel@rigel.com)

SOURCE Rigel Pharmaceuticals, Inc.